Read more

April 12, 2024
1 min read
Save

Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • VTX-801 is an investigational gene therapy to treat Wilson’s disease.
  • Cohort 2 dosing allowed after Independent Data Monitoring Committee approval.

A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease.

According to a release from Vivet Therapeutics, GATEWAY is a nonrandomized, open-label study conducted across several clinical sites in the United States, United Kingdom, Germany and Denmark. The trial seeks to assess the safety, tolerability and pharmacological activity of a single IV infusion of VTX-801, a novel, investigational gene therapy, at increasing dose levels in adult patients with Wilson’s disease.

hand, tongs, DNA animation
European-based Vivet Therapeutics has dosed the first patient in cohort of its ongoing phase 1/2 clinical trial of a novel, investigationaI gene therapy. Image: Adobe Stock

Initiation of cohort 2 followed the successful completion of cohort 1 and subsequent approval from an independent data monitoring committee to proceed, the company said.

“We are encouraged by the initial safety, histological and pharmacodynamic data that VTX-801 has demonstrated to date, and we are pleased that the first patient has been successfully dosed in Cohort 2 in the GATEWAY clinical trial,” Jean-Philippe Combal, CEO at Vivet Therapeutics, stated in the release. “2024 is shaping up to be a transformative year for Vivet and its gene therapy platform and we look forward to providing further data on our GATEWAY clinical trial at upcoming scientific conferences.”